NASDAQ:OTLK

Outlook Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy OTLK

*Your capital is at risk

$0.81

-0.0038 (-0.467%)

At Close: Jun 03, 2026

Outlook Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 67.11. In total, the insiders bought 83.97M and sold 18.95M OTLK shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	67.11
● Buy	83.97M shares
● Sell	18.95M shares
96% Buy Activity Negligible or No Correlation
Buy Signal High Confidence May 28, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 67.11. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (96% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Oct 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Gangolli Julian S Director	Director	286 734 Value: $298.2K
Oct 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Haddadin Yezan Munther Director	Director	286 734 Value: $298.2K
Oct 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Auffarth Gerd Director	Director	286 734 Value: $298.2K
Oct 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Thurman Randy H Director	Director	286 734 Value: $298.2K
Oct 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Sukhtian Faisal Ghiath Director	Director	286 734 Value: $298.2K
Oct 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Sukhtian Faisal Ghiath Director	Director	286 734 Value: $298.2K
Oct 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Thurman Randy H Director	Director	286 734 Value: $298.2K
Oct 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Auffarth Gerd Director	Director	286 734 Value: $298.2K
Oct 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Haddadin Yezan Munther Director	Director	286 734 Value: $298.2K
Oct 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Gangolli Julian S Director	Director	286 734 Value: $298.2K
Oct 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Hilzinger Kurt J Director	Director	286 734 Value: $298.2K
Oct 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Haller Julia A Director	Director	286 734 Value: $298.2K
Oct 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Huang Andong Director	Director	286 734 Value: $298.2K
Jul 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Jahr Robert Charles Chief Executive Officer	CEO / President	800 000 Value: $1.26M
Jul 01, 2025 Buy	Common Stock J-Other	Jahr Robert Charles Insider	Other	0 Value: $0
Jul 01, 2025 Buy	Common Stock J-Other	Jahr Robert Charles Insider	Other	0 Value: $0
Jul 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Jahr Robert Charles Chief Executive Officer	CEO / President	800 000 Value: $1.26M
May 27, 2025 Buy	Common Stock A-Award	Sukhtian Ghiath M.	Director	4 285 714 Value: $6.00M
May 27, 2025 Buy	Warrants (right to buy) A-Award	Sukhtian Ghiath M.	Director	8 571 428 Value: $12.0M
May 27, 2025 Buy	Warrants (right to buy) A-Award	Sukhtian Ghiath M.	Director	8 571 428 Value: $12.0M
May 27, 2025 Buy	Common Stock A-Award	Sukhtian Ghiath M.	Director	4 285 714 Value: $6.00M
Feb 04, 2025 Buy	Stock Option (Right to Buy) A-Award	Sukhtian Faisal Ghiath Director	Director	12 323 Value: $22.5K
Feb 04, 2025 Buy	Stock Option (Right to Buy) A-Award	Sukhtian Faisal Ghiath Director	Director	12 323 Value: $22.5K
Jan 17, 2025 Buy	Common Stock M-Exempt	Sukhtian Ghiath M.	Director	3 458 571 Value: $8.68M
Jan 17, 2025 Buy	Common Stock M-Exempt	Sukhtian Ghiath M.	Director	3 458 571 Value: $8.68M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT OUTLOOK THERAPEUTICS INC.

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and lice...

Read Full Profile Here